
WHAT IS CLAIMED IS:

1. A compound of Formula I, or a pharmaceutically acceptable salt thereof, having a structure according to the following formula:



(I)

wherein


R^1 is an unsubstituted aryl, an aryl substitude with 1 to 4 substituents selected from the group consisting of halo, cyano, substituted or unsubstituted C_1-C_6 alkyl, and substituted or unsubstituted C_1-C_6 haloalkyl, a substituted or unsubstituted benzyl, or a substituted or unsubstituted adamant-l-yl;

X is selected from $–N(R^{14})-C(=O)–$, or $–N(R^{14})-S(=O)_k–$, or $–CH_2-N(R^{14})-C(=O)–$, or $–CH_2-N(R^{14})-S(=O)_k–$, or $–C(=O)-N(R^{14})–$, and $–CH_2-C(=O)-N(R^{14})–$;


k is selected from 1 and 2; and

R^{14} is H or substituted or unsubstituted C_1-C_6 alkyl;

R^2 is



or



;

R^3, R^4, R^5, R^6, R^7, R^8, R^9, and R^{10} are each independently hydrogen, substituted or unsubstituted -C_{1-6} alkyl, or substituted or unsubstituted -C_{1-6} haloalkyl


R^{12} and R^{13} are each independently hydrogen, fluorine, substituted or unsubstituted-C_{1-6} alkyl, substituted or unsubstituted-C_{1-6} haloalkyl; and

R^{11} and either R^{12} or R^{13}, together with the carbons to which they are attached, form a 3-, 4-, 5-, 6- or 7-membered substituted or unsubstituted cycloalkyl group.

2. The compound according to claim **1**, or a pharmaceutically acceptable salt thereof, wherein R^1 is an aryl substituted by 1, 2, 3 or 4 substituents selected from halo, substituted or unsubstituted C_{1-6} haloalkyl, substituted or unsubstituted C_{1-6} alkyl, and cyano.

3. The compound according to claim **1**, or a pharmaceutically acceptable salt thereof, wherein the aryl in R^1 is phenyl.

4. The compound according to claim **1**, or a pharmaceutically acceptable salt thereof, having a structure according to the following formula:




wherein

R^{11a} and R^{11b} are members each independently selected from H, unsubstituted C_1-C_3 alkyl, and halogen;

q is an integer selected from 1, 2, 3, 4 and 5.

5. The compound according to claim **4**, or a pharmaceutically acceptable salt thereof, wherein R^{11a} and R^{11b} are members each independently selected from H, methyl, and fluorine.

6. The compound according to claim **4**, or a pharmaceutically acceptable salt thereof having a structure according to the following formula:




wherein

q is an integer selected from 1, 2, 3, 4 and 5.

7. The compound according to claim **4**, or a pharmaceutically acceptable salt thereof, wherein R^1 is substituted or unsubstituted benzyl or substituted or unsubstituted adamantyl.


8. The compound according to claim **4**, or a pharmaceutically acceptable salt thereof, having a structure according to the following formula:




.

9. The compound according to claim **8**, or a pharmaceutically acceptable salt thereof, wherein q is 1 or 2.


10. The compound according to claim **9** which is




or



or




or




.


11. The compound according to claim **8** which is




or



or











or







.


12. The compound according to claim **8** which is:



or

or

or

or

or

or

or

.


13. The compound according to claim **4**, or a pharmaceutically acceptable salt thereof, wherein R^1 is phenyl substituted with one to three substituents, each of which is a member selected from the group consisting of F, Cl, and CF_3.


14. The compound according to claim **4**, or a pharmaceutically acceptable salt thereof, which is:


or

or

or

or



or



or



or



or


wherein R^{1a} and R^{1b} are members each independently selected from the group consisting of F, Cl, and CF_3.


15. The compound according to claim **1**, or a pharmaceutically acceptable salt thereof, which is:





or



or



or



or


or












or


or




or


or



or



or

or

or

or

or

or

, wherein R^1 is unsubstituted adamant-1-yl, or

, wherein R^1 is unsubstituted adamant-1-yl, or

or

.

16. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, which is


or

.


17. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, which is



or


.

18. A compound of Formula I, or a pharmaceutically acceptable salt thereof, having a structure according to the following formula:



(I)

wherein

R^1 is an aryl which is meta-disubstituted with substituents selected from the group consisting of halo and haloalkyl, or R^1 is a substituted or unsubstituted adamant-l-yl;

X is selected from $–N(R^{14})-C(=O)–$, or $–N(R^{14})-S(=O)_k–$, or $–CH_2-N(R^{14})-C(=O)–$, or $–CH_2-N(R^{14})-S(=O)_k–$, or $–C(=O)-N(R^{14})–$, and $–CH_2-C(=O)-N(R^{14})–$;

k is selected from 1 and 2; and


R^{14} is H or substituted or unsubstituted C_1-C_6 alkyl;

R^2 is a monosubstituted methyl or ethyl group;

R^3, R^4, R^5, R^6, R^7, R^8, R^9, and R^{10} are each independently hydrogen, substituted or unsubstituted -C_{1-6} alkyl, or substituted or unsubstituted -C_{1-6} haloalkyl;

R^{12} and R^{13} are each independently hydrogen, fluorine, substituted or unsubstituted-C_{1-6} alkyl, substituted or unsubstituted-C_{1-6} haloalkyl; and


R^{11} and either R^{12} or R^{13}, together with the carbons to which they are attached, form a 3-, 4-, 5-, 6- or 7-membered substituted or unsubstituted cycloalkyl group.

19. The compound according to claim **18**, or a pharmaceutically acceptable salt thereof, wherein R^1 is , and wherein R^{1a} and R^{1b} are members each independently selected from the group consisting of halogen and haloalkyl.

20. The compound according to claim **19**, or a pharmaceutically acceptable salt thereof, wherein R^{1a} and R^{1b} are members each independently selected from the group consisting of F, Cl, and CF_3.

21. The compound according to claim **18**, or a pharmaceutically acceptable salt thereof, wherein R^2 is a monosubstituted methyl or ethyl group substituted with a substituent selected from the group consisting of fluoro, chloro, bromo, iodo, –(C_1-C_4) alkyl, –(C_1-C_4) haloalkyl, –C(═O)NH (straight or branched C_1-C_4 alkyl), and –NHC(═O) (straight or branched C_1-C_4 alkyl).

22. The compound according to claim **18**, or a pharmaceutically acceptable salt thereof, having a structure according to the following formula:




wherein

R^{11a} and R^{11b} are members each independently selected from H, unsubstituted C_1-C_3 alkyl, and halogen;

q is an integer selected from 1, 2, 3, 4 and 5.


23. The compound according to claim **22**, or a pharmaceutically acceptable salt thereof, wherein R^{11a} and R^{11b} are members each independently selected from H, methyl, and fluorine.

24. The compound according to claim **22**, or a pharmaceutically acceptable salt thereof having a structure according to the following formula:



wherein q is an integer selected from 1, 2, 3, 4 and 5.


25. The compound according to claim **22**, or a pharmaceutically acceptable salt thereof, having a structure according to the following formula:



.


26. The compound according to claim **5**, or a pharmaceutically acceptable salt thereof, wherein q is 1 or 2.

27. The compound according to claim **25** which is



.

28. The compound according to claim **27**, or a pharmaceutical acceptable salt thereof, wherein

R^1 is 

,

R^{1a} and R^{1b} are members each independently selected from the group consisting of F, Cl, and CF_3, and

R^2 is a monosubstituted methyl or ethyl group substituted with a substituent selected from the group consisting of fluoro, chloro, bromo, iodo, –(C_1-C_4) alkyl, –(C_1-C_4) haloalkyl, –C(═O)NH (straight or branched C_1-C_4 alkyl), and –NHC(═O) (straight or branched C_1-C_4 alkyl).

29. A pharmaceutical formulation comprising a therapeutically effective amount of a compound according to claim **1** or claim **18**, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

30. The pharmaceutical formulation according to claim **29**, wherein said formulation is in a unit dosage format.

31. Use of the compound according to claim **1** or claim **18**, or a pharmaceutical formulation thereof, in the preparation of a medicament for the treatment of pain, epilepsy or essential tremor in a human.

32. The compound according to claim **1** or claim **18**, or a pharmaceutical formulation thereof, for use in therapy.

33. The use of claim **31** or the compound of claim **32**, wherein the compound selectively inhibits the T Channel known as the $Ca_{v3.2}$ channel.

34. The use of claim **31**, wherein the pain is neuropathic or inflammatory pain.